Alembic Pharmaceuticals has announced the first prescription-based sale of Pivya (pivmecillinam) tablets following its recent commercial launch in the United States.
The launch marks a significant milestone for the company as Pivya becomes Alembic’s first branded pharmaceutical product in the US market. The product is being marketed through Alembic Therapeutics LLC, a wholly owned subsidiary of Alembic.
This move signals the company’s strategic entry into the US branded specialty pharmaceuticals segment.
Pivya is an oral prescription antibiotic indicated for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women.
The drug contains pivmecillinam, a beta-lactam antibacterial agent with a long track record of clinical use globally.
It is specifically indicated for infections caused by susceptible strains of:
These pathogens are among the most common causes of uncomplicated urinary tract infections in women.
Uncomplicated UTIs remain one of the most common bacterial infections among women in the United States. Key market insights include:
With rising concerns around antibiotic resistance and appropriate antibiotic stewardship, established therapies such as pivmecillinam are gaining renewed attention as effective first-line treatment options.
According to Pranav Amin, Managing Director of Alembic Pharmaceuticals, the launch represents the first step in the company’s broader US strategy.
Alembic plans to build a focused branded specialty portfolio in the US while continuing to expand its established generics business.
The company has already:
Alembic also plans a phased expansion of its field sales force as prescription demand grows.
The US remains the largest pharmaceutical market in the world, making it a key strategic focus for global drug manufacturers.
Alembic is pursuing a balanced growth approach, combining:
The commercial launch of Pivya is expected to serve as the foundation for building a long-term branded business platform in the US.
Founded in 1907, Alembic Pharmaceuticals is a vertically integrated pharmaceutical company headquartered in India. The company focuses on:
Alembic currently markets its medicines in multiple international markets, with the United States representing one of its most important growth regions.
Bottom line:
The first US prescription sales of Pivya (pivmecillinam) mark Alembic Pharmaceuticals’ entry into the branded specialty drug market in the United States, opening a new growth avenue beyond its established generics business.